Reagan Kelly - Concepedia

Author

Reagan Kelly

United States Food and Drug Administration ORCID

Also Known As

R J Kelly, R Kelly, Reagan J Kelly, Reagan J. Kelly, Reagan Kelly, Liqing Wan

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration National Center for Toxicological Research University of Michigan ICF International (United States)Medizinische Hochschule Hannover

About

Reagan Kelly is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	793
2	Health Sciences	2	2	224
3	Biochemistry	2	2	224
4	Public Health	1	1	115
5	Biostatistics	1	1	96

Reagan Kelly

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure Stephen B. Liggett, Sharon Cresci, Reagan Kelly, Nature Medicine Molecular PharmacologyCardiomyopathyHeart FailureMolecular PhysiologyCardiovascular Disease	2008	320
Molecular basis for H blood group deficiency in Bombay (Oh) and para-Bombay individuals. Reagan Kelly, Robert D. Larsen, J G Bryant, Proceedings of the National Academy of Sciences ImmunohematologyGeneticsBlood Group LociImmunologyGlycobiology	1994	190
Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure Sharon Cresci, Reagan Kelly, Thomas P. Cappola, Journal of the American College of Cardiology CardiomyopathyHeart FailureCardiorenal SyndromesCardiovascular DiseaseGenetics	2009	115
Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs Minjun Chen, Huixiao Hong, Hong Fang, Toxicological Sciences	2013	113
Translating Clinical Findings into Knowledge in Drug Safety Evaluation - Drug Induced Liver Injury Prediction System (DILIps) Zhichao Liu, Qiang Shi, Don Ding, PLoS Computational Biology Drug Safety EvaluationNew Drug CandidatesClinical FindingsPharmacotherapyAdverse Drug Reaction	2011	96
The Liver Toxicity Knowledge Base: A Systems Approach to a Complex End Point M Chen, J Zhang, Y Wang, Clinical Pharmacology & Therapeutics	2013	86
Investigating drug repositioning opportunities in FDA drug labels through topic modeling Halil Bişğin, Zhichao Liu, Reagan Kelly, BMC Bioinformatics	2012	77
A phenome-guided drug repositioning through a latent variable model Halil Bişğin, Zhichao Liu, Hong Fang, BMC Bioinformatics	2014	49
atBioNet– an integrated network analysis tool for genomics and biomarker discovery Yijun Ding, Minjun Chen, Zhichao Liu, BMC Genomics	2012	44
Hypertrophy‐Associated Polymorphisms Ascertained in a Founder Cohort Applied to Heart Failure Risk and Mortality Afshin Parsa, Yen‐Pei C. Chang, Reagan Kelly, Clinical and Translational Science	2011	44

Page 1